Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) EBITDA (2016 - 2025)

Moleculin Biotech's EBITDA history spans 10 years, with the latest figure at $15.6 million for Q4 2025.

  • Quarterly results put EBITDA at $15.6 million for Q4 2025, up 335.42% from a year ago — trailing twelve months through Dec 2025 was -$23.9 million (down 4.11% YoY), and the annual figure for FY2025 was -$33.5 million, down 28.49%.
  • EBITDA for Q4 2025 was $15.6 million at Moleculin Biotech, up from -$25.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $15.6 million in Q4 2025 to a low of -$25.4 million in Q3 2025.
  • The 5-year median for EBITDA is -$6.5 million (2024), against an average of -$6.1 million.
  • Peak annual rise in EBITDA hit 335.42% in 2025, while the deepest fall reached 262.41% in 2025.
  • Year by year, EBITDA stood at -$2.8 million in 2021, then crashed by 139.5% to -$6.8 million in 2022, then crashed by 51.97% to -$10.3 million in 2023, then soared by 35.48% to -$6.6 million in 2024, then skyrocketed by 335.42% to $15.6 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $15.6 million, -$25.4 million, and -$7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.